Skip To Main Content
Simon Spichak on Muck Rack

Simon Spichak

Verified
(He/Him)
Toronto
As seen in: Illumination, Medium, MSN, MSN UK, The Startup, Yahoo Life, Nature, The Guardian, Yahoo Canada, Yahoo News and
Covers:  Neuroscience, health, microbiome, neurotechnology, drug development, blockchain, biology, immunology
Neuroscience MSc 🦔 dad Founded @Resolvve_inc Words in Being Patient, National Geographic, MIT Tech Review, The Sick Times, JMIR etc.

Get in touch with Simon

Contact Simon, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Simon Spichak’s Biography

Read Full Bio →

Hi! I'm an award-winning science communicator and science. I completed my MSc in neuroscience in 2021, focusing on the way that microbes in the gut communicate with the brain. I also represented Ireland on the international stage at Fame Lab - a science communication competition where scientists explain complex topics in a few minutes. I want to leverage my knowledge of science, statistics, and effective communication to explain complex subjects to non-experts.

Simon Spichak’s Journalist Portfolio

See all →
We Might Be Treating Schizophrenia All Wrong

We Might Be Treating Schizophrenia All Wrong

For more than 70 years, doctors treated the symptoms of schizophrenia-delusions, hallucinations, cognitive im…

View article →
Will This Drug Help Us Beat Alzheimer’s? Or Will It Doom Its Makers Instead?

Will This Drug Help Us Beat Alzheimer’s? Or Will It Doom Its Makers Instead?

View article →
Crypto Mines Are Making Life a 'Daily Hell' in This Town

Crypto Mines Are Making Life a 'Daily Hell' in This Town

"The natural beauty and tranquility of our area is in jeopardy," C. Roberson's petition on Change.org reads. …

View article →
How Crypto Is Failing Spectacularly to Greenwash Itself

How Crypto Is Failing Spectacularly to Greenwash Itself

"Imagine if keeping your car idling 24/7 produced solved Sudokus you could trade for heroin." That's how one …

View article →
Why Is Everyone So Mad About Aduhelm? - Being Patient

Why Is Everyone So Mad About Aduhelm? - Being Patient

Helped assemble a 2018 consortium that led to a biomarker-based definition of Alzheimer's, controversial beca…

View article →
Startups Are Rushing to Prescribe a New Weight Loss Drug, But Questions Remain

Startups Are Rushing to Prescribe a New Weight Loss Drug, But Questions Remain

For Zoe, it started with a news article. The Food and Drug Administration (FDA) had approved a new weight los…

View article →

Articles

“Miracle on the Hudson” Pilot Sully Sullenberger Diagnosed with Alzheimer’s

|
By Simon Spichak Verified
| Being Patient Verified
On January 15th, 2009, both engines on US Airways Flight 1549 shut down after a bird strike shortly after takeoff. Chesley “Sully” Sullenberger landed the plane on the Hudson River, saving all 155 people on board, with news outlets calling the event the “Miracle on the Hudson.” Sullenberger used the fame afforded by his heroism to speak about aviation safety. Earlier this month, Sullenberger, now 75, revealed he was diagnosed with early-stage Alzheimer’s in August 2025.
Open in Who Shared Issue with article?

How to interpret clinical trial results for Long COVID

|
By Simon Spichak Verified
| The Sick Times
Heather Hogan / The Sick Times Key points you should know: There are currently no approved treatments for Long COVID. Experts say that the diversity of symptoms and severity makes it more difficult to run clinical trials. Trials of new drugs and devices are stratified by phases. Only phase 3 trials are designed to prove that a treatment is effective.
Open in Who Shared Issue with article?

A Glimpse of the Future from the Alzheimer’s Association International Conference

|
By Simon Spichak Verified
| Being Patient Verified
At AAIC 2026, researchers made headway on tau therapies and biomarkers, showcased the evolution of lifestyle prevention trials, and presented emerging research on other dementias. Last week, over 11,000 experts gathered in London for the Alzheimer’s Association International Conference (AAIC). While data from promising Phase 2 trials and Alzheimer’s blood tests dominated the headlines, the week featured other advances that progress treatment and care for the disease.
Open in Who Shared Issue with article?
See all 628 licensed articles (633 Total)